Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
肿瘤血管内皮生长因子 A 的过度表达可能预示着贝伐单抗和厄洛替尼在耐药性卵巢癌中的 II 期试验进展可能性增加
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-10-0974
Setsuko K Chambers, Mary C Clouser, Amanda F Baker, Denise J Roe, Haiyan Cui, Molly A Brewer, Kenneth D Hatch, Michael S Gordon, Mike F Janicek, Jeffrey D Isaacs, Alan N Gordon, Raymond B Nagle, Heather M Wright, Janice L Cohen, David S Alberts
